Literature DB >> 28133005

Impact of Branched-Chain Amino Acid-Enriched Nutrient on liver Cirrhosis with Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization in Barcelona Clinic Liver Cancer Stage B: A Prospective Study.

Shunichi Shiozawa1, Takebumi Usui, Kotaro Kuhara, Akira Tsuchiya, Tatsuomi Miyauchi, Teppei Kono, Shinichi Asaka, Kentaro Yamaguchi, Hajime Yokomizo, Takeshi Shimakawa, Kazuhiko Yoshimatsu, Takao Katsube, Yoshihiko Naritaka.   

Abstract

BACKGROUND: In decompensated liver cirrhosis, hypoalbuminemia still persists even after they have been treated with branched-chain amino acid (BCAA) granules. We prospectively evaluated whether BCAA enriched nutrient switched from BCAA granules would increase the serum albumin level, and consequently extend the survival time after hepatocellular carcinoma (HCC) treatment.
METHODS: This study included 77 patients treated for liver cirrhosis with HCC. After the nutritional assessment, all patients initially received BCAA granules. In patients with unchanged or decreased serum albumin levels, BCAA granules were discontinued and BCAA enriched nutrient was started. Transcatheter arterial chemembolization (TACE) for HCC were performed in those with an improved Child-Pugh score.
RESULTS: TACE were performed following the aggressive intervention with BCAA nutritional education in 54 of 77 (70.1%) patients. Finally, survival time was significantly extended in the TACE group (P<0.0001).
CONCLUSION: Timely aggressive nutritional intervention in Barcelona Clinic Liver Cancer stage B HCC, namely, early partial replacement with BCAA enriched nutrient may consequently improve the treatment outcome of HCC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28133005     DOI: 10.1272/jnms.83.248

Source DB:  PubMed          Journal:  J Nippon Med Sch        ISSN: 1345-4676            Impact factor:   0.920


  9 in total

1.  Differential diagnosis between hepatocellular carcinoma and cirrhosis by serum amino acids and acylcarnitines.

Authors:  Yong Zhang; Nan Ding; Yunfeng Cao; Zhitu Zhu; Peng Gao
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

Review 2.  KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-07-09

3.  The regulation of healthspan and lifespan by dietary amino acids.

Authors:  Reji Babygirija; Dudley W Lamming
Journal:  Transl Med Aging       Date:  2021-05-24

Review 4.  Amino acids in cancer.

Authors:  Elizabeth L Lieu; Tu Nguyen; Shawn Rhyne; Jiyeon Kim
Journal:  Exp Mol Med       Date:  2020-01-24       Impact factor: 8.718

5.  BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism.

Authors:  Lifang Luo; Wenjing Sun; Weijian Zhu; Shuhan Li; Wenqi Zhang; Xiaohui Xu; Daoquan Fang; Tan Hooi Min Grahn; Lei Jiang; Yihu Zheng
Journal:  Cell Death Dis       Date:  2021-02-10       Impact factor: 8.469

6.  The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization.

Authors:  Tzu-Ping Chien; Song-Fong Huang; Wen-Hui Chan; Kuang-Tse Pan; Ming-Chin Yu; Wei-Chen Lee; Hsin-I Tsai; Po-Ting Lin; Hsing-Yu Chen; Jui-Hsuan Chen; Chao-Wei Lee
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

Review 7.  Branched-chain amino acid metabolism in cancer.

Authors:  Elitsa A Ananieva; Adam C Wilkinson
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2018-01       Impact factor: 4.294

8.  Phosphorylation of BCKDK of BCAA catabolism at Y246 by Src promotes metastasis of colorectal cancer.

Authors:  Qin Tian; Ping Yuan; Chuntao Quan; Mingyang Li; Juanjuan Xiao; Lu Zhang; Hui Lu; Tengfei Ma; Ling Zou; Fei Wang; Peipei Xue; Xiaofang Ni; Wei Wang; Lin Liu; Zhe Wang; Feng Zhu; Qiuhong Duan
Journal:  Oncogene       Date:  2020-04-01       Impact factor: 9.867

9.  Onodera's prognostic nutritional index is a strong prognostic indicator for patients with hepatocellular carcinoma after initial hepatectomy, especially patients with preserved liver function.

Authors:  Akihiro Tanemura; Shugo Mizuno; Aoi Hayasaki; Kazuyuki Gyoten; Takehiro Fujii; Yusuke Iizawa; Hiroyuki Kato; Yasuhiro Murata; Naohisa Kuriyama; Masashi Kishiwada; Hiroyuki Sakurai; Shuji Isaji
Journal:  BMC Surg       Date:  2020-10-31       Impact factor: 2.102

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.